PharmaEssentia Announces Updated NCCN Clinical Practice Guidelines Include ropeginterferon alfa-2b-njft (BESREMi®) for Treatment of Essential Thrombocythemia (ET), by . PharmaEssentia USA Corporation.
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Taiwan’s PharmaEssentia has committed $46 million to build a Puerto Rico drug manufacturing facility to serve the U.S. market ...
On Monday, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the Phase 3 VERIFY study of rusfertide for polycythemia vera.
Nuvisertib received FDA fast track designation for myelofibrosis, showing significant clinical activity in symptom and spleen response, and improvements in bone marrow fibrosis, hemoglobin, and ...
A novel treatment for polycythemia vera, a potentially fatal blood cancer, demonstrated the ability to control overproduction of red blood cells, the hallmark of this malignancy and many of its ...
In part 3 of a discussion with Andrew Kuykendall, MD, Moffitt Cancer Center, he talks of rusfertide’s ability to enable patients to live a more viable life and free them from being tethered to the ...
You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: My husband (age 71) received a diagnosis of polycythemia ...
While treatment options may be fairly straightforward for high-risk patients with polycythemia vera, it’s less clear for patients who are considered low risk, explained Jennifer Vaughn, MD. Patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results